|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
CTD_human |
CD276 and the alternative checkpoint inhibition PVR/NECTIN2/CD226/TIGIT pathway emerged as relevant to PC checkpoint inhibition target development.
|
30614027 |
2019 |
|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
BEFREE |
CD276 and the alternative checkpoint inhibition PVR/NECTIN2/CD226/TIGIT pathway emerged as relevant to PC checkpoint inhibition target development.
|
30614027 |
2019 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Taken together, these results indicated that B7‑H2‑ and/or B7‑H3‑positive expression indicates a poor clinical outcome for patients, and the combination of B7‑H2 and B7‑H3 may be a preferential prognostic biomarker in patients with HCC.
|
30942404 |
2019 |
|
Malignant neoplasm of prostate
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Here we used genomic expression data to examine the relationship between B7-H3 mRNA expression and prostate cancer.
|
27801901 |
2017 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Early Detection of Hepatocellular Carcinoma in Patients with Hepatocirrhosis by Soluble B7-H3.
|
28243980 |
2017 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Involvement of soluble B7-H3 in combination with the serum inflammatory cytokines interleukin-17, -8 and -6 in the diagnosis of hepatocellular carcinoma.
|
29344257 |
2017 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the expression of B7-H3 in tissues and cells of primary hepatocellular carcinoma (PHC) patients.
|
24787022 |
2014 |
|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
BEFREE |
In conclusion, blocking mtDNA replication by EtBr induces increased expression of stemness genes, such as Oct3/4, Nanog, CD44, and ABCG2, in addition to the immune regulator B7-H3 in PC-3 and DU145 prostate cancer cell lines.
|
23634795 |
2013 |
|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
BEFREE |
B7-H3 in tissue samples was significantly higher in the prostate cancer group than in the benign prostatic hyperplasia group (mean±SEM 174.73±56.80 vs 82.69±46.19 ng/gm, p<0.001).
|
21784485 |
2011 |
|
Malignant neoplasm of prostate
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of coinhibitory B7x and B7-H3 in prostate cancer correlates with poor disease outcome, whereas tumor-infiltrating immune cells have enhanced expression of PD-L1 and its receptor PD-1.
|
20971039 |
2011 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Large subcutaneous H22 HCCs (0.7-0.8 cm in diameter) established in BALB/c mice were rapidly and completely eradicated when intratumoral administration of As(2)O(3) was preceded by in situ gene transfer of B7H3.
|
16217749 |
2006 |
|
Liver carcinoma
|
0.350 |
Therapeutic
|
disease |
CTD_human |
Large subcutaneous H22 HCCs (0.7-0.8 cm in diameter) established in BALB/c mice were rapidly and completely eradicated when intratumoral administration of As(2)O(3) was preceded by in situ gene transfer of B7H3.
|
16217749 |
2006 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Identification of targets for prostate cancer immunotherapy.
|
30614027 |
2019 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nevertheless, the clinical significance of B7-H3 expression in colorectal cancer (CRC) remains unclear.
|
31424670 |
2020 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
B7-H3 expression was correlated with TNM stage and metastasis.
|
31424670 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7-H3 expression was statistically correlated with patient gender (p = .0297), tumor histopathological subtypes (p = .0262) and radiotherapy after surgery (p = .0028).
|
31629137 |
2020 |
|
Malignant neoplasm of colon and/or rectum
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum miR-1301-3p, miR-335-5p, miR-28-5p, and their target B7-H3 may serve as novel biomarkers for colorectal cancer.
|
31424670 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study reports novel functions of B7-H3 in regulating breast cancer stem cell enrichment.
|
30082909 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In particular, B7-H3 (CD276), a cellular receptor expressed in breast cancer, was imaged via sPA and fluorescence molecular imaging to differentiate invasive tumors from normal glands in mice.
|
31082216 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study provides an overview of the immune checkpoint pathways, including CTLA-4, PD-1, lymphocyte activation gene 3, T-cell immunoglobulin and mucin domain 3, B7-H3, and diacylglycerol kinase α and implications of their inhibition in the cancer therapy.
|
30511409 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7-H3 is abnormally overexpressed in many types of cancer and is generally associated with a poor clinical prognosis.
|
31222741 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7-H3 belongs to the B7 family of immunoregulatory proteins, and the overexpression of B7-H3 is found in various types of cancer.
|
30664982 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results indicated that B7-H3 was positively stained in most of the clinical glioma samples, and its expression levels were correlated to the malignancy grade and poor survival in both low-grade glioma (LGG) and GBM patients.
|
31485480 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preclinical B7-H3-targeted RIT studies have also shown encouraging therapeutic outcomes in a variety of solid malignancies.
|
30836909 |
2019 |